Published in Ann Microbiol (Paris) on July 01, 1978
Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet (1985) 13.47
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53
Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science (1985) 3.81
Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal disease. Proc Natl Acad Sci U S A (1989) 3.66
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res (2003) 3.22
Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). Rheumatology (Oxford) (2006) 2.57
HTLV-I/II antibodies in French blood donors. Lancet (1990) 2.54
Effect of CO(2), O(2), and Light on Photosynthesis and Photorespiration in Wheat. Plant Physiol (1980) 2.48
Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa. Lancet (1986) 2.48
Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis (1999) 2.32
Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet (1981) 2.31
Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst (1990) 2.23
The epidemiology of conjunctival squamous cell carcinoma in Uganda. Br J Cancer (2002) 2.18
Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet (1986) 2.14
Characterization of Streptococcus agalactiae strains by multilocus enzyme genotype and serotype: identification of multiple virulent clone families that cause invasive neonatal disease. J Clin Microbiol (1995) 2.13
Benign notochordal cell tumour: case report. Diagn Interv Imaging (2013) 1.99
Adipose tissues as an ancestral immune organ: site-specific change in obesity. FEBS Lett (2005) 1.96
Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet (1988) 1.95
New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM). Science (1986) 1.91
Kinetics of delta antigen and delta antibody in acute delta hepatitis: evaluation with different enzyme immunoassays. J Clin Microbiol (1988) 1.87
Relapse of herpes simplex encephalitis. J Child Neurol (1995) 1.66
Endemic tropical spastic paraparesis associated with human T-lymphotropic virus type I: a clinical and seroepidemiological study of 25 cases. Ann Neurol (1987) 1.63
Aetiology of AIDS--antibodies to human T-cell leukaemia virus (type III) in haemophiliacs. Nature (1984) 1.63
Antibody to hepatitis-B core antigen in patients with primary hepatic carcinoma. Lancet (1975) 1.62
Urogenital, maternal and neonatal isolates of Haemophilus influenzae: identification of unusually virulent serologically non-typable clone families and evidence for a new Haemophilus species. J Gen Microbiol (1990) 1.59
Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology (1986) 1.59
Human T-lymphotropic virus type 4 and the human immunodeficiency virus in West Africa. Science (1987) 1.58
Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis (2003) 1.58
Evidence for activation of cellular immune responses in patients with acute hepatitis E. Indian J Gastroenterol (2002) 1.54
Intractable hiccup as the initial presenting feature of systemic lupus erythematosus. Lupus (2005) 1.53
Survival of very preterm infants: Epipage, a population based cohort study. Arch Dis Child Fetal Neonatal Ed (2004) 1.52
Hepatitis delta virus infection in French male HBsAg-positive homosexuals. Hepatology (1989) 1.51
Genetic diversity of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis revealed by restriction fragment length polymorphism of the rRNA gene region. J Clin Microbiol (1995) 1.46
Cell therapy based on adipose tissue-derived stromal cells promotes physiological and pathological wound healing. Arterioscler Thromb Vasc Biol (2009) 1.46
Cross-sectional and longitudinal epidemiology of hepatitis B in Senegal. Prog Med Virol (1981) 1.45
In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res (1998) 1.44
[Fatal alveolar haemorrhage following a "bang" of cannabis]. Rev Mal Respir (2011) 1.44
Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping. AIDS Res Hum Retroviruses (1996) 1.42
Genetic characterization of a cryptic genospecies of Haemophilus causing urogenital and neonatal infections. J Clin Microbiol (1993) 1.41
Altered macrophage-like functions of preadipocytes in inflammation and genetic obesity. J Cell Physiol (2001) 1.41
CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction. Am J Transplant (2013) 1.40
[Evaluation of preoperative non-invasive ventilation in thoracic surgery for lung cancer: the preOVNI study GFPC 12-01]. Rev Mal Respir (2012) 1.39
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.38
[Congenital aneurysm of the trunk of the pulmonary artery]. J Radiol (1999) 1.38
Fine-needle percutaneous biopsy of renal masses with helical CT guidance. Radiology (2000) 1.38
Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood (1999) 1.37
Both pre-S1 and S domains of hepatitis B virus envelope proteins interact with the core particle. Virology (1997) 1.36
Prevalence of human T-lymphotropic retroviruses type III (HIV) and type IV in Ivory Coast. Lancet (1987) 1.35
Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis (1986) 1.35
Immunisation against hepatitis B in man. Lancet (1976) 1.31
Typing of urogenital, maternal, and neonatal isolates of Haemophilus influenzae and Haemophilus parainfluenzae in correlation with clinical source of isolation and evidence for a genital specificity of H. influenzae biotype IV. J Clin Microbiol (1989) 1.29
Thymic abnormalities in fetuses aborted from human immunodeficiency virus type 1 seropositive women. Pediatrics (1992) 1.28
Ultrastructural and physicochemical characterization of the hepatitis C virus recovered from the serum of an agammaglobulinemic patient. Arch Virol (1998) 1.28
European health systems and cancer care. Ann Oncol (2003) 1.27
Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues. J Gen Virol (1981) 1.26
Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL49 (VP22) and UL48 (VP16) genes: high-level expression and characterization of MDV-1 VP22 and VP16. J Gen Virol (2000) 1.25
The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol (1998) 1.25
Emergence during development of the white-adipocyte cell phenotype is independent of the brown-adipocyte cell phenotype. Biochem J (2001) 1.24
Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology (1997) 1.24
Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol (2007) 1.22
[Quantitative estimate of the risk of blood donation contamination by infectious agents]. Transfus Clin Biol (2009) 1.21
HIV-1 diversity in France, 1996-1998. The AC 11 laboratory network. AIDS (2000) 1.21
Structure of the gene of tum- transplantation antigen P35B: presence of a point mutation in the antigenic allele. EMBO J (1990) 1.21
Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol (1987) 1.21
Identification of a novel hepatitis E virus in Nigeria. J Gen Virol (2000) 1.21
Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol (2000) 1.20
Viral envelope protein of HTLV-III is the major target antigen for antibodies in hemophiliac patients. J Infect Dis (1986) 1.20
Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett (2001) 1.19
Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol (2001) 1.17
Human immunodeficiency virus antigenemia in patients with AIDS and AIDS-related disorders: a comparison between European and Central African populations. J Infect Dis (1987) 1.17
Hepatitis B virus DNA in primary hepatocellular carcinoma tissue. J Med Virol (1978) 1.17
Immunogenic nature of a Pol gene product of HTLV-III/LAV. Blood (1987) 1.17
Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells. FEMS Microbiol Lett (1994) 1.17
Comparison of DNA enzyme immunoassay and line probe assays (Inno-LiPA HCV I and II) for hepatitis C virus genotyping. J Clin Microbiol (1998) 1.17
False positive result of Mycobacterium tuberculosis complex DNA probe hybridization with a Mycobacterium terrae isolate. Eur J Clin Microbiol Infect Dis (1993) 1.16
Immune response to synthetic peptides of hepatitis delta antigen. J Clin Microbiol (1993) 1.16
[Pituitary metastasis presenting as diabetes insipidus: a report of four cases and literature review]. Rev Med Interne (2009) 1.15
Human papillomavirus vaccines. Semin Cancer Biol (1999) 1.13
Enzyme-linked oligosorbent assay for detection of polymerase chain reaction-amplified human immunodeficiency virus type 1. J Clin Microbiol (1993) 1.13
Frequent and early in utero HIV-1 infection. AIDS Res Hum Retroviruses (1991) 1.13
Active immunization against hepatitis B in an area of high endemicity. Part I: Field design. Prog Med Virol (1981) 1.12